| Literature DB >> 32284011 |
Akiko Matsutani1,2, Chihiro Udagawa2, Yuki Matsunaga1, Seigo Nakamura1, Hitoshi Zembutsu2.
Abstract
The widespread use of breast screening programs has contributed to the detection of early stage breast cancer, which is often asymptomatic. Early diagnosis is essential to avoid overtreatment and improve clinical outcomes, as early stage breast cancer is rarely life-threatening if detected quickly. Despite this, tissue biopsy remains the principle method for detecting these cancers. Liquid biopsy has been recently proposed as a promising detection method in oncology that is not only less invasive but also contributes to the early diagnosis of breast cancer. Here, we describe the clinical utility of liquid biopsy as a tool for the early detection of breast cancer.Entities:
Keywords: biomarker; breast cancer; circulating tumor DNA; ductal carcinoma in situ; liquid biopsy; radiogenomics
Year: 2020 PMID: 32284011 DOI: 10.2217/pgs-2019-0130
Source DB: PubMed Journal: Pharmacogenomics ISSN: 1462-2416 Impact factor: 2.533